Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

The Role of Lipids in Immune Cell Function in SLE Patients

22 april 2020 bijgewerkt door: University College, London

Understanding the Role Played by Serum and Membrane Lipids in Immune Cell Function in Patients With Systemic Lupus Erythematosus (SLE) and Healthy Donors

The overall aim of this project is to investigate the different types of immune cells found in the blood of patients with Systemic Lupus Erythematosus (SLE) and healthy donors. We know that the amount of fat on the surface of immune cells is an important factor controlling their behaviour. Immune cells from SLE patients are defective and this is associated with changes in the levels of fat on these cells. This project will investigate the level of fat in the blood and on immune cells from patients with SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave.

Studie Overzicht

Gedetailleerde beschrijving

Accelerated atherosclerosis is a serious complication of autoimmunity including patients with both adult and juvenile onset systemic lupus erythematosus (SLE). This suggests that defects in fat levels could contribute to disease pathogenesis. The immune system in patients with SLE does not work normally. In adult patients with SLE we know that many of the immune cells involved in protecting the body from infections or cancer are over-active and actually cause disease. In young people the immune system is still developing and very little is known about what goes wrong in patients that develop juvenile-onset SLE, whether this is the same as adult disease and whether the same treatments are relevant for this group of patients. This project aims to find out whether immune cells from SLE patients with adult-onset disease have the same defects as adult patients with juvenile-onset SLE. We know that an important factor that controls immune cell behaviour is the amount of fat that they have on their surface. We also know that a change in fat on immune cells from adult patients with SLE makes them defective. This project will investigate the level of fat in the blood and in immune cells from adult patients with juvenile-onset SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave. We will investigate how drugs that control fat levels can help to normalize the behaviour of immune cells from SLE patients.

Studietype

Observationeel

Inschrijving (Verwacht)

300

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • London, Verenigd Koninkrijk, NW1 2BU
        • Werving
        • University College London Hospitals NHS Foundation Trust
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • David Isenberg, Prof

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

NVT

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients will be approached by the consultant rheumatologist when the patient is attending their normal outpatient clinic appointment.

Healthy donors will be approached in a similar way using information flyers, invitation letters and participant information sheets by a member of the research team.

Healthy volunteers from UCL staff will be made aware of the study and also asked to participate.

Beschrijving

Inclusion Criteria:

  • Diagnosis of SLE according to American College of Rheumatology revised criteria
  • Having given written informed consent prior to undertaking any study-related procedures.
  • Male and female patients between the ages of 18 and 80 years.

Patients who have met all the above inclusion criteria listed and healthy donors will be screened for the following exclusion criteria:

Exclusion Criteria:

  • Under any administrative or legal supervision.
  • Conditions/situations such as:
  • A concomitant autoimmune disease
  • Impossibility to meet specific protocol requirements (e.g. blood sampling).
  • Patient is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
  • Uncooperative or any condition that could make the patient potentially non-compliant to the study procedures.
  • Pregnant or breast-feeding women, currently or in the last three months prior to inclusion.
  • Patients who have been vaccinated in the last three months prior to inclusion.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Juvenile onset Systemic Lupus Erythematosus (SLE) patients
All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 11 and 21.
  • Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
  • Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.
  • Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Andere namen:
  • Food Frequency Questionnaires (FFQs) and/or 24 hour diet recall questionnaires
  • Ultrasound Scan (USS)
  • GTN (glyceryl trinitrate) administration
Adult onset Systemic Lupus Erythematosus (SLE) patients
All patients who meet the American College of Rheumatology revised criteria for SLE who were diagnosed with SLE between the ages of 24 and 80
  • Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
  • Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.
  • Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Andere namen:
  • Food Frequency Questionnaires (FFQs) and/or 24 hour diet recall questionnaires
  • Ultrasound Scan (USS)
  • GTN (glyceryl trinitrate) administration
Matching healthy volunteers
Healthy volunteers, matched by age and gender, will be used as a control group
  • Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
  • Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake.
  • Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Andere namen:
  • Food Frequency Questionnaires (FFQs) and/or 24 hour diet recall questionnaires
  • Ultrasound Scan (USS)
  • GTN (glyceryl trinitrate) administration

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Collection of blood samples
Tijdsspanne: 4 hours from point of sample collection
Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers.
4 hours from point of sample collection
Completion of FFQ's and/or diet recall questionnaires
Tijdsspanne: Same day as recruited to study.
FFQ's and/or diet recall questionnaires to assess dietary intake
Same day as recruited to study.
Cardiovascular Ultrasound scans (USS)
Tijdsspanne: Within 2 months from recruitment.
USS of Intima Media Thickness (IMT), Flow Mediated Dilatation (FMD), Pulse Wave Velocity (PWV) and Laser Doppler Flowmetry measurement. As part of the procedure, sub lingual administration of GTN spray will be administered to measure FMD.
Within 2 months from recruitment.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: David Isenberg, Prof, UCL & University College London Hospitals NHS Foundation Trust

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 februari 2016

Primaire voltooiing (Verwacht)

31 augustus 2020

Studie voltooiing (Verwacht)

31 augustus 2020

Studieregistratiedata

Eerst ingediend

22 april 2020

Eerst ingediend dat voldeed aan de QC-criteria

22 april 2020

Eerst geplaatst (Werkelijk)

24 april 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 april 2020

Laatste update ingediend die voldeed aan QC-criteria

22 april 2020

Laatst geverifieerd

1 april 2020

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

All participants are required to indicate in written consent if they agree to the use of any left over samples and associated data for future research use.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren